Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
RadioTherapeutics acquisition announced Nov. 8 includes a radiofrequency ablation system for non-resectable liver lesions. Boston Scientific has distributed the system in the U.S. for radiological applications under a 1998 strategic alliance. Terms of the deal, set to close in December, were not disclosed...
You may also be interested in...
Boston Scientific Inks Smart Therapeutics Deal, Closes On Radiotherapeutics
Boston Scientific plans to combine its GDC aneurysm coils with Smart Therapeutics, Inc.'s development-phase intracranial stent system to better treat intracranial aneurysmal disease under a definitive acquisition agreement, announced Dec. 13
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.